Selective Antiproliferative and Apoptotic Effects of 2,6‐Diketopiperazines on MDA ‐ MB ‐231 Triple‐Negative Breast Cancer
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Flor Paulina Garrido González und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Departamento de Química, Ciudad de México, México. Hauptthemen laut MEDLINE: Diketopiperazines, Apoptosis, Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diketopiperazines (DKPs) have emerged as promising candidates for treating diverse diseases, particularly cancer. In this context, 2,5‐diketopiperazines have been extensively investigated in comparison with 2,6‐diketopiperazines. This work explores the selectivity and impact of 2,6‐diketopiperazine enantiomers derived from α‐amino acids on MDA‐MB‐231 triple‐negative breast cancer cells (TNBC). This subtype of cancer is recognized for its aggressiveness and the lack of effective therapeutic options. The evaluation utilized MTT and flow cytometry assays to examine the impact of 2,6‐DPKs on the MDA‐MB‐231 breast cancer cell line. The obtained IC 50 values for compounds 1 and ( S )‐enantiomers ranged from 4.6 μM to 4.944 mM, where 1 and ( S )‐ 2a exhibited the lowest values. The IC 50 values for ( R ) enantiomers ranged from 0.021 to 3.639 mM, whereas ( R )‐ 2b was the lowest. Flow cytometry results revealed that compounds increase in apoptosis at 48 h compared to 24 h, ranging from 54.1% to 76.2%; however, ( S )‐ 12a exhibited a 3% decrease in apoptotic induction at 48 h. All investigated 2,6‐diketopiperazines derived from α‐amino acids showed potential as anticancer agents against MDA‐MB‐231 cancer cells. In particular, compounds 1 , ( S )‐ 2a , ‐4a, and ‐ 5a showed remarkable inhibitory effects on proliferation, viability, and apoptosis. The MTT results in the culture of healthy cells of the kidney line Vero did not display cytotoxicity at the tested concentrations up to 12.0 mM. Hence, these 2,6‐DPKs are suitable for in vivo testing shortly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Departamento de Química, Ciudad de México, México.
- Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Escuela, Superior de Medicina, Plan de San Luis y Diaz Mirón, Ciudad de México, México.
ORCID-Profile: Elvia Mera Jiménez, Teresa Mancilla Percino
Zitieren
APA
Garrido González, F. P., Macías Pérez, M. E., Rodríguez Cortés, O., Mera Jiménez, E., & Mancilla Percino, T. (2025). Selective Antiproliferative and Apoptotic Effects of 2,6‐Diketopiperazines on MDA ‐ MB ‐231 Triple‐Negative Breast Cancer. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70098
Vancouver
Garrido González FP, Macías Pérez ME, Rodríguez Cortés O, Mera Jiménez E, Mancilla Percino T. Selective Antiproliferative and Apoptotic Effects of 2,6‐Diketopiperazines on MDA ‐ MB ‐231 Triple‐Negative Breast Cancer. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70098
BibTeX
@article{GarridoGonzlez2025,
author = {Garrido González, Flor Paulina and Macías Pérez, Martha Edith and Rodríguez Cortés, Octavio and Mera Jiménez, Elvia and Mancilla Percino, Teresa},
title = {Selective Antiproliferative and Apoptotic Effects of 2,6‐Diketopiperazines on MDA ‐ MB ‐231 Triple‐Negative Breast Cancer},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70098}
}
EUVIMED